Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis

被引:50
作者
Tilg, Herbert [1 ]
机构
[1] Innsbruck Med Univ, Christian Doppler Res Lab Gut Inflammat, A-6020 Innsbruck, Austria
关键词
Cytokines; obesity; fatty liver disease; inflammation; INSULIN-RESISTANCE; ADIPOSE-TISSUE; WEIGHT-LOSS; ADIPONECTIN; STEATOHEPATITIS; OBESITY; PROTEIN; LEPTIN; TRIAL;
D O I
10.2174/138161210791208929
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of the metabolic syndrome and covers a large spectrum of liver diseases ranging from benign steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. The pathogenesis of NAFLD is currently believed to involve various hits including lipotoxicity, gut- derived signals, inflammatory attacks directed by pro-inflammatory cytokines, oxidative stress and others. All these factors finally lead to the development of necroinflammation and fibrosis in a substantial proportion of patients. There is increasing evidence that mediators released from the adipose tissue in obese subjects, such as adipocytokines and classical cytokines, are key players in NAFLD. The prototypic adipocytokines adiponectin and leptin are able to regulate many features of NAFLD such as accumulation of liver fat, insulin resistance, inflammatory processes and development of fibrosis. Therefore, this heterogenous and rapidly growing family of mediators elegantly explains many aspects of NAFLD as demonstrated by numerous experimental and clinical studies.
引用
收藏
页码:1893 / 1895
页数:3
相关论文
共 35 条
[1]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[2]   Long-Term Mortality in Nonalcoholic Fatty Liver Disease: Is Liver Histology of Any Prognostic Significance? [J].
Angulo, Paul .
HEPATOLOGY, 2010, 51 (02) :373-375
[3]   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[4]   Role of Adipocytokines in Hepatic Fibrosis [J].
Bertolani, C. ;
Marra, F. .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) :1929-1940
[5]   Does retinol-binding protein 4 cause or reflect fatty liver disease? [J].
Blueher, Matthias ;
Toenjes, Anke ;
Stumvoll, Michael .
HEPATOLOGY, 2008, 48 (01) :4-6
[6]   Insulin Resistance in Nonalcoholic Fatty Liver Disease [J].
Bugianesi, E. ;
Moscatiello, S. ;
Ciaravella, M. F. ;
Marchesini, G. .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) :1941-1951
[7]   Bariatric surgery for non-alcoholic steatohepatitis in obese patients [J].
Chavaez-Tapia, N. C. ;
Tellez-Avila, F., I ;
Barrientos-Gutierrez, T. ;
Mendez-Sanchez, N. ;
Lizardi-Cervera, J. ;
Uribe, M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01)
[8]   Role of microRNAs in Non-Alcoholic Steatohepatitis [J].
Cheung, Onpan ;
Sanyal, Arun J. .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) :1952-1957
[9]   Recent advances in nonalcoholic fatty liver disease [J].
Cheung, Onpan ;
Sanyal, Arun J. .
CURRENT OPINION IN GASTROENTEROLOGY, 2009, 25 (03) :230-237
[10]   Current and Future Therapeutic Strategies in NAFLD [J].
de Alwis, Nimantha Mark Wilfred ;
Day, Christopher Paul .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) :1958-1962